Filippo Montemurro

Feb 23, 2023 | cancertreatmentreviews.com | Volkmar Müller |Rupert Bartsch |Nancy Lin |Filippo Montemurro

Monoclonal antibodyNCT01004172*[54]Leone J.P. Emblem K.E. Weitz M. Gelman R.S. Schneider B.P. Freedman R.A. et al. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Phase 2, single-arm, open-label trialBevacizumab (monotherapy 15 mg/kg IV on cycle 1 day 1) + carboplatin (IV, AUC = 5, on cycle 1 day 8; HER2– cohort only). Patients with HER2-positive disease also received trastuzumab (8 mg/kg load if indicated; otherwise, 6 mg/kg on cycle 1 day 8).